AI Project Extended to Enhance Predictions for Drug-Resistant Epilepsy
Researchers at King's College London, led by Professor Mark Richardson, have secured further funding to extend their AI-driven project aimed at identifying risk factors for drug-resistant epilepsy. The project, supported by the Epilepsy Research Institute and Angelini Pharma, will continue for an additional 16 months.
The team has developed advanced AI tools to analyze electronic health records (EHRs) from NHS hospitals. They have already annotated records of 5,556 epilepsy patients and are set to analyze an additional 4,774 records. This large-scale data analysis seeks to uncover previously unidentified risk factors for refractory epilepsy, a condition where seizures persist despite medication.
The extension will allow researchers to expand their dataset and refine AI methodologies, with a goal of analyzing up to 30,000 patient records across three London hospitals. This effort aims to provide deeper insights into the predictors of refractory epilepsy, potentially leading to new prevention strategies and personalized treatment plans.
The Epilepsy Research Institute will continue to oversee the grant and project management. This initiative highlights the collaborative effort to advance epilepsy research through innovative AI technologies and extensive data analysis.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice Operations Oct 15 Study Tracks 270 Million Clinical AI Queries on OpenEvidence Oct 15 OpenAI Offers US University Labs Free GPT-Rosalind AccessLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
ARPA-H Funds $28.6 Million AI Protein Research Project
Elsevier Pledges 4,000 AI Tool Licenses for European Researchers
AI in Clinical Trials Market Forecast to Reach USD 7.32 Billion by 2034
Brainomix and Pulmonary Fibrosis Foundation Partner on AI Lung Imaging Research
UK Medicines Regulator Plans AI Safety Tools by 2030
Daily AI Brief: the AI news that matters, in your inbox.